Clinical trials: Mild Cognitive Impairment
Mild Cognitive Impairment
Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery
The primary objective is to compare mild cognitive impairment in the AL-208 group with the placebo group at 14 + - 3 days after CABG surgery
- Trial name
- NCT00404014
- Testing
- AL-208
- Where
- 28 sites in United States, Canada
- Volunteers
- 234 people
- Sponsor
- Allon Therapeutics
Alzheimer's Disease
Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
The purpose of this study is to demonstrate that donepezil slows the progression of Alzheimer's disease (AD) using magnetic resonance imaging (MRI) of the brain to measure the volume of the hippocampus in patients with…
- Trial name
- NCT00403520
- Testing
- Experimental 1
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Mild Cognitive Impairment
Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or…
- Trial name
- NCT04191486
- Testing
- T-817MA
- Where
- 37 sites in Czechia, Germany and 5 more
- Volunteers
- 221 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED (NCT04828122)
- Where
- 4 sites in United Kingdom
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Mild Cognitive Impairment
Exploratory Trial in Healthy Adults With Mild Cognitive Impairment,16-week Intervention With Mitocholine™
To evaluate the effect of 16-weeks consumption of Mitocholine on Executive Function and Homocysteine levels in a population experiencing Mild Cognitive Impairment.
- Trial name
- NCT05690724
- Where
- Ireland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mitocholine Ltd
Mild Cognitive Impairment, Alzheimer's Disease
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
This study is being conducted to determine the safety, tolerability, pharmacokinetics, and effects of EVP-0962 on cerebral spinal fluid Amyloid concentrations in healthy subjects and in subjects with mild cognitive impairment or…
- Trial name
- NCT01661673
- Testing
- EVP-0962
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- FORUM Pharmaceuticals Inc
Mild Cognitive Impairment
Navigating the Clinical Research Process for Mild Cognitive Impairment
Participation in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
- Trial name
- NCT06207903
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Dementia Alzheimers
Feasibility Study of Game Technology in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
This study will test G:DATA, a simple computer game designed to diagnose Alzheimer's Disease, in three different groups of people, some of whom have Alzheimer's Disease.
- Trial name
- G:DATA (NCT06047340)
- Testing
- G:DATA, dementia screen videogame
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ascentys Ltd
Mild Cognitive Impairment (MCI), Amnestic Mild Cognitive Impairment - aMCI
Auditory Stimulation During Sleep to Enhance Long-Term Memory in Amnestic MCI
This study aims to evaluate the efficacy and safety of Elevvo AudiStim, a sleep auditory stimulation device, as a symptomatic treatment for patients with amnestic mild cognitive impairment (aMCI).
- Conditions
- Mild Cognitive Impairment (MCI), Amnestic Mild Cognitive Impairment - aMCI, Alzheimer or Mild Cognitive Impairment
- Trial name
- NCT07402590
- Testing
- Auditory Stimulation
- Where
- Spain
- Volunteers
- 37 people
- Sponsor
- Bitbrain
Alzheimer's Disease
Computer-Based Training for Mild Alzheimer's Disease
The primary objective of this study is to evaluate the effects of computer-based training program ("HiFi-AD") on the memory and cognitive abilities of individuals diagnosed with mild Alzheimer's Disease (AD).
- Trial name
- NCT00319891
- Testing
- Computer-based Cognitive Training
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Posit Science Corporation
Mild Cognitive Impairment, Ischemic Stroke
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
The purpose of this study is: to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke to evaluate safety of MMH-MAP in the treatment of mild…
- Trial name
- NCT03815292
- Testing
- MMH-MAP
- Where
- 28 sites in Russia
- Volunteers
- 276 people
- Sponsor
- Materia Medica Holding
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Alzheimer's Disease
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).
- Trial name
- NCT05463731
- Testing
- Remternetug (IV), Remternetug (SC)
- Where
- 76 sites in United States, Japan
- Volunteers
- 1,667 people
- Sponsor
- Eli Lilly and Company
Vascular Dementia, Mild Cognitive Impairment
Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment
This clinical trial evaluates the preliminary effectiveness and safety of Cerogrin, a medical device developed by Neurogrin Inc.
- Trial name
- NCT07149038
- Testing
- Cerogrin
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Neurogrin Inc.
Alzheimer Disease
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of…
- Trial name
- NCT04971733
- Testing
- E2814
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Alzheimer Disease, Mild Cognitive Impairment
Software Validation Study-Cognitive Status Indicator
The SPARK Cognitive Status Indicator software uses an algorithm to assess a resting state EEG recording as being consistent with a cognitive status of unimpaired, mild cognitive impairment (MCI; MCI AD- or MCI AD+), or dementia…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- REMIND-V (NCT06809725)
- Testing
- SPARK Cognitive Status Indicator (software support data collected via EEG)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Spark Neuro Inc.
Mild Cognitive Impairment, Alzheimer Disease
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide.
- Trial name
- NCT03461276
- Testing
- ABvac40
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 134 people
- Sponsor
- Araclon Biotech S.L.
Mild Cognitive Impairment, Alzheimer Disease
Alzheimer's and Blood Glucose Levels
The Alzheimer's and Blood Glucose Levels Study is researching the differences in blood glucose levels between people with and without Mild Cognitive Impairment or Alzheimer's disease with the aim of early detection of Alzheimer's…
- Trial name
- NCT04614376
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bio Conscious Technologies Inc.
Mild Cognitive Impairment
Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain.
- Trial name
- NCT00040443
- Testing
- CX516
- Where
- 8 sites in United States
- Volunteers
- 175 people
- Sponsor
- RespireRx